Payment overview · 2025
General Payments
$157.42
9 reported records · 8 companies
Healthcare provider profile · identity verified
James Dull Rutter, MD
Allopathic & Osteopathic Physicians|Internal Medicine · GROVE, OK · NPI 1649258369
Verified facts
What the public records show
CMS Open Payments records show James Dull Rutter, MD received $157.42 in general payments during 2025 across 9 reported records.
Supernus Pharmaceuticals, Inc. accounted for 22.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Entresto, Mounjaro.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 106 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Entresto by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 144 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $35.49 | 22.5% | 2 | 2025 |
| Globus Medical, Inc. | Unresolved — no canonical attribution shown | $25.31 | 16.1% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$18.77 | 11.9% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $15.85 | 10.1% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $15.84 | 10.1% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $15.67 | 9.9% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $15.49 | 9.8% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $15.00 | 9.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $157.42 | 9 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $35.49 | 2 | 2025 |
Source payment records
|
|||||
| Senza Normalized: senza |
Device | Globus Medical, Inc. | $25.31 | 1 | 2025 |
Source payment records
|
|||||
| INTERSTIM Normalized: interstim |
Device | Medtronic, Inc. | $18.77 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $15.85 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $15.85 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $15.85 | 1 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $15.84 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $15.67 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $15.49 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $15.49 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $15.00 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $15.00 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ENTRESTO entresto |
2025 | Entresto | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 106 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
106 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
47 | 12 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
144 | 38 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 807 | 252 |
| Losartan Potassium | Losartan Potassium | 557 | 176 |
| Levothyroxine Sodium | Levothyroxine Sodium | 555 | 155 |
| Pantoprazole Sodium | Pantoprazole Sodium | 359 | 113 |
| Amlodipine Besylate | Amlodipine Besylate | 355 | 112 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 295 | 100 |
| Lisinopril | Lisinopril | 295 | 95 |
| Metoprolol Succinate | Metoprolol Succinate | 264 | 95 |
| Hydrochlorothiazide | Hydrochlorothiazide | 260 | 80 |
| Furosemide | Furosemide | 250 | 95 |
| Gabapentin | Gabapentin | 245 | 85 |
| Metformin Hcl | Metformin Hcl | 230 | 68 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 227 | 75 |
| Omeprazole | Omeprazole | 220 | 72 |
| Trazodone Hcl | Trazodone Hcl | 189 | 62 |
| Meloxicam | Meloxicam | 181 | 65 |
| Tamsulosin Hcl | Tamsulosin Hcl | 181 | 59 |
| Escitalopram Oxalate | Escitalopram Oxalate | 162 | 46 |
| Clopidogrel | Clopidogrel Bisulfate | 156 | 50 |
| Fluticasone Propionate | Fluticasone Propionate | 154 | 76 |
| Eliquis | Apixaban | 144 | 38 |
| Potassium Chloride | Potassium Chloride | 144 | 59 |
| Carvedilol | Carvedilol | 143 | 50 |
| Finasteride | Finasteride | 143 | 41 |
| Celecoxib | Celecoxib | 141 | 43 |
| Duloxetine Hcl | Duloxetine Hcl | 141 | 45 |
| Simvastatin | Simvastatin | 131 | 32 |
| Alprazolam | Alprazolam | 128 | 30 |
| Metoprolol Tartrate | Metoprolol Tartrate | 121 | 41 |
| Allopurinol | Allopurinol | 120 | 37 |
| Alendronate Sodium | Alendronate Sodium | 118 | 25 |
| Atenolol | Atenolol | 111 | 36 |
| Doxazosin Mesylate | Doxazosin Mesylate | 111 | 33 |
| Zolpidem Tartrate | Zolpidem Tartrate | 110 | 30 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 106 | 49 |
| Mounjaro | Tirzepatide | 106 | 19 |
| Buspirone Hcl | Buspirone Hcl | 102 | 27 |
| Ozempic | Semaglutide | 100 | 27 |
| Baclofen | Baclofen | 98 | 29 |
| Ventolin Hfa | Albuterol Sulfate | 94 | 23 |
| Mirtazapine | Mirtazapine | 82 | 27 |
| Clonazepam | Clonazepam | 80 | 13 |
| Temazepam | Temazepam | 80 | 20 |
| Montelukast Sodium | Montelukast Sodium | 77 | 29 |
| Pregabalin | Pregabalin | 73 | 22 |
| Ipratropium Bromide | Ipratropium Bromide | 71 | 27 |
| Donepezil Hcl | Donepezil Hcl | 68 | 23 |
| Sertraline Hcl | Sertraline Hcl | 68 | 26 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 67 | 25 |
| Pravastatin Sodium | Pravastatin Sodium | 67 | 21 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 67 | 22 |
| Enalapril Maleate | Enalapril Maleate | 66 | 21 |
| Glimepiride | Glimepiride | 66 | 20 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 65 | 13 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 64 | 56 |
| Memantine Hcl | Memantine Hcl | 64 | 17 |
| Metformin Hcl Er | Metformin Hcl | 63 | 23 |
| Prednisone | Prednisone | 63 | 41 |
| Quetiapine Fumarate | Quetiapine Fumarate | 63 | 12 |
| Famotidine | Famotidine | 62 | 23 |
| Citalopram Hbr | Citalopram Hydrobromide | 59 | 19 |
| Ropinirole Hcl | Ropinirole Hcl | 59 | 19 |
| Pioglitazone Hcl | Pioglitazone Hcl | 57 | 15 |
| Warfarin Sodium | Warfarin Sodium | 57 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 56 | 17 |
| Breo Ellipta | Fluticasone/Vilanterol | 55 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 55 | 21 |
| Hydralazine Hcl | Hydralazine Hcl | 54 | 18 |
| Ezetimibe | Ezetimibe | 53 | 21 |
| Ondansetron Odt | Ondansetron | 52 | 20 |
| Spironolactone | Spironolactone | 52 | 21 |
| Diazepam | Diazepam | 51 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 51 | 16 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 49 | 15 |
| Trulicity | Dulaglutide | 47 | 12 |
| Xarelto | Rivaroxaban | 47 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 46 | 15 |
| Sucralfate | Sucralfate | 45 | 26 |
| Bupropion Xl | Bupropion Hcl | 43 | 14 |
| Synthroid | Levothyroxine Sodium | 43 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 42 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 41 | 16 |
| Estradiol | Estradiol | 40 | suppressed |
| Ibuprofen | Ibuprofen | 40 | 18 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 39 | suppressed |
| Valsartan | Valsartan | 38 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 37 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 35 | suppressed |
| Jardiance | Empagliflozin | 35 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 34 | 28 |
| Mupirocin | Mupirocin | 33 | 16 |
| Oxybutynin Chloride | Oxybutynin Chloride | 33 | 12 |
| Tizanidine Hcl | Tizanidine Hcl | 33 | 11 |
| Propranolol Hcl | Propranolol Hcl | 31 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 31 | 22 |
| Amiodarone Hcl | Amiodarone Hcl | 30 | 11 |
| Eszopiclone | Eszopiclone | 30 | suppressed |
| Sotalol | Sotalol Hcl | 30 | suppressed |
| Bumetanide | Bumetanide | 29 | 13 |
| Naproxen | Naproxen | 28 | suppressed |
| Lovastatin | Lovastatin | 27 | suppressed |
| Januvia | Sitagliptin Phosphate | 26 | suppressed |
| Lorazepam | Lorazepam | 26 | suppressed |
| Myrbetriq | Mirabegron | 26 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 25 | suppressed |
| Nystatin | Nystatin | 25 | 11 |
| Methotrexate | Methotrexate Sodium | 24 | suppressed |
| Nitroglycerin | Nitroglycerin | 24 | 12 |
| Propranolol Hcl Er | Propranolol Hcl | 24 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 24 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 22 | suppressed |
| Ibu | Ibuprofen | 22 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 21 | suppressed |
| Levofloxacin | Levofloxacin | 21 | 19 |
| Roflumilast | Roflumilast | 21 | suppressed |
| Topiramate | Topiramate | 21 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 21 | suppressed |
| Acyclovir | Acyclovir | 20 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Novolog Flexpen | Insulin Aspart | 20 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 20 | suppressed |
| Repatha Sureclick | Evolocumab | 20 | suppressed |
| Levetiracetam | Levetiracetam | 19 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 19 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 19 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 19 | suppressed |
| Azithromycin | Azithromycin | 18 | 17 |
| Fluconazole | Fluconazole | 18 | 16 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 18 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 18 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 18 | suppressed |
| Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Ramipril | Ramipril | 18 | suppressed |
| Rybelsus | Semaglutide | 18 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 18 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 18 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 17 | suppressed |
| Entresto | Sacubitril/Valsartan | 17 | suppressed |
| Glipizide | Glipizide | 17 | suppressed |
| Irbesartan | Irbesartan | 16 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 16 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 15 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 15 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 14 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Fenofibrate | Fenofibrate | 14 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 14 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 14 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 13 | suppressed |
| Glipizide Er | Glipizide | 13 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 13 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Cephalexin | Cephalexin | 12 | 11 |
| Gemfibrozil | Gemfibrozil | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 12 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 11 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 11 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Gemtesa | Vibegron | 11 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 11 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $157.42 · 9 records | Supernus Pharmaceuticals, Inc. | ABRYSVO, COMIRNATY, ENTRESTO, INTERSTIM, MOUNJARO, OTEZLA, PREVNAR 20, Qelbree, REPATHA, REXULTI, Senza, ZEPBOUND | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Entresto play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error